Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Allarity Therapeutics Inc (ALLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: ALLR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.25
1 Year Target Price $9.25
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.28M USD | Price to earnings Ratio 0.21 | 1Y Target Price 9.25 |
Price to earnings Ratio 0.21 | 1Y Target Price 9.25 | ||
Volume (30-day avg) 1 | Beta 0.24 | 52 Weeks Range 0.61 - 2.06 | Updated Date 02/21/2026 |
52 Weeks Range 0.61 - 2.06 | Updated Date 02/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.03% | Return on Equity (TTM) -150.58% |
Valuation
Trailing PE 0.21 | Forward PE - | Enterprise Value -348677 | Price to Sales(TTM) - |
Enterprise Value -348677 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.08 | Shares Outstanding 14524080 | Shares Floating 14594636 |
Shares Outstanding 14524080 | Shares Floating 14594636 | ||
Percent Insiders 2.9 | Percent Institutions 3.73 |
Upturn AI SWOT
Allarity Therapeutics Inc
Company Overview
History and Background
Allarity Therapeutics Inc. was founded in 2007 (as ARZERRA AB, later renamed to Oncopeptides AB and subsequently Allarity Therapeutics AB). The company has undergone several transformations and rebrandings. It was initially focused on developing treatments for hematological cancers, with a significant focus on multiple myeloma. In more recent times, it has pivoted to focus on precision medicine in oncology, aiming to identify the right treatment for the right patient at the right time. A key development was its merger with Rakel Therapeutics in 2023, which led to the current entity focused on companion diagnostics and targeted therapies.
Core Business Areas
- Precision Oncology: Allarity Therapeutics focuses on developing and commercializing companion diagnostics and targeted therapies for cancer patients. Their approach involves identifying specific genetic or molecular biomarkers to predict patient response to certain treatments.
- Drug Development Pipeline: The company has a pipeline of drug candidates and is actively involved in clinical trials to advance these therapies.
Leadership and Structure
The leadership team and organizational structure are subject to change, particularly following recent mergers and restructuring. Specific details on current key personnel would require access to the most up-to-date company filings and official announcements.
Top Products and Market Share
Key Offerings
- DoseSELECTu00ae Platform: Allarity's proprietary DoseSELECTu00ae platform is designed to personalize cancer treatment by predicting which patients are most likely to benefit from specific therapies. This platform aims to reduce treatment failures and improve patient outcomes. Market share data is not readily available as this is a platform technology and diagnostic service rather than a standalone product with traditional market share metrics. Competitors would include other companies offering companion diagnostics and personalized medicine solutions in oncology, such as Foundation Medicine (a subsidiary of Roche), Guardant Health, and Caris Life Sciences.
- Drug Candidates in Pipeline: Allarity Therapeutics has several drug candidates in various stages of clinical development. Specific details on individual drug candidate performance, revenue generation, or market share are not applicable at this stage as they are still under development. Competitors for these drug candidates would depend on the specific indication and therapeutic area.
Market Dynamics
Industry Overview
The precision oncology market is a rapidly growing segment of the pharmaceutical and biotechnology industry. It is characterized by advancements in genomic sequencing, molecular diagnostics, and targeted therapies. The industry is driven by the increasing understanding of cancer biology and the demand for more effective and less toxic treatments. Key trends include the development of companion diagnostics, liquid biopsies, and novel therapeutic modalities.
Positioning
Allarity Therapeutics positions itself as a leader in precision oncology through its innovative DoseSELECTu00ae platform and its focus on matching patients with the most effective treatments. Its competitive advantage lies in its ability to integrate diagnostic capabilities with therapeutic development, aiming to optimize treatment selection and improve patient outcomes. The company competes with other biopharmaceutical companies and diagnostic providers in the oncology space.
Total Addressable Market (TAM)
The Total Addressable Market for precision oncology is substantial and growing, encompassing the global oncology market with an increasing emphasis on personalized treatment approaches. Estimates vary, but the global precision oncology market is projected to reach tens of billions of dollars in the coming years. Allarity Therapeutics aims to capture a segment of this market by providing diagnostic tools and targeted therapies that improve treatment efficacy and patient selection.
Upturn SWOT Analysis
Strengths
- Proprietary DoseSELECTu00ae platform for personalized cancer treatment.
- Focus on a rapidly growing and high-demand market (precision oncology).
- Integration of diagnostic and therapeutic development capabilities.
- Potential for improved patient outcomes and reduced healthcare costs.
Weaknesses
- Relatively early stage of development for many pipeline assets.
- Dependence on clinical trial success and regulatory approvals.
- Limited historical financial performance and revenue generation.
- Potential for significant cash burn due to R&D expenses.
Opportunities
- Increasing adoption of precision medicine in oncology.
- Expansion of its diagnostic platform to new indications and therapies.
- Strategic partnerships with larger pharmaceutical companies for drug development and commercialization.
- Advancements in genomic sequencing and biomarker discovery.
Threats
- Intense competition in the oncology and precision medicine space.
- Regulatory hurdles and delays in clinical trials and approvals.
- Changes in healthcare reimbursement policies.
- Technological advancements by competitors that could render current approaches obsolete.
- Patent expirations of existing therapies.
Competitors and Market Share
Key Competitors
- Foundation Medicine (FMI) (a subsidiary of Roche)
- Guardant Health (GH)
- Caris Life Sciences
- Thermo Fisher Scientific (TMO) (Diagnostics Division)
- Roche (RHHBY)
Competitive Landscape
Allarity Therapeutics faces a highly competitive landscape in precision oncology. Its advantages lie in its integrated diagnostic-therapeutic approach and potentially novel biomarkers. However, it faces established players with significant resources, larger market penetration, and extensive product portfolios. Key disadvantages might include its smaller scale, less diversified pipeline, and longer time to market for some of its offerings compared to larger, more established competitors.
Growth Trajectory and Initiatives
Historical Growth: Historically, Allarity Therapeutics (and its predecessor entities) has focused on building its research capabilities and advancing its drug development pipeline. Growth has been characterized by scientific progress, clinical trial initiation, and strategic collaborations or mergers.
Future Projections: Future growth projections are heavily dependent on the successful outcomes of its ongoing clinical trials, regulatory approvals, and the commercialization of its therapeutic candidates and diagnostic platform. Analyst estimates, if available, would provide specific growth forecasts.
Recent Initiatives: Recent initiatives include the merger with Rakel Therapeutics to strengthen its precision oncology focus, ongoing clinical trials for its drug candidates, and efforts to expand its DoseSELECTu00ae platform.
Summary
Allarity Therapeutics Inc. is positioned in the promising precision oncology market, leveraging its DoseSELECTu00ae platform to personalize cancer treatment. While its focus on matching the right patient with the right therapy is a strong strategic advantage, the company faces significant competition and the inherent risks of drug development. Its success hinges on the clinical validation and regulatory approval of its pipeline and diagnostic tools. Continued investment in R&D and strategic partnerships will be crucial for navigating the competitive landscape and achieving sustainable growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (e.g., SEC filings)
- Financial news outlets
- Biotechnology industry reports
- Market research databases
Disclaimers:
This JSON output is generated for informational purposes only and does not constitute financial advice. The data provided is based on publicly available information and may not be exhaustive or entirely up-to-date. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is estimated and may not reflect precise current figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allarity Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-12-21 | Founder, CEO & Director Mr. Thomas H. Jensen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.allarity.com |
Full time employees 6 | Website https://www.allarity.com | ||
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.